In one paragraphArticle in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
16 authors.
Simeon PlatteGoethe University Frankfurt, University Hospital, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Frankfurt, Germany.ORCID 0009-0001-3429-8306 Afsheen KumarGoethe University Frankfurt, University Hospital, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Frankfurt, Germany.ORCID 0000-0002-8026-7332 Giorgia GueriniLaboratory of Experimental Neurology, Université Libre de Bruxelles, Brussels, Belgium.
Massimo PandolfoLaboratory of Experimental Neurology, Université Libre de Bruxelles, Brussels, Belgium.ORCID 0000-0001-5230-5787 Denise HaslingerGoethe University Frankfurt, University Hospital, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Frankfurt, Germany.ORCID 0000-0002-1859-4295 Colin B JosephsonDepartment of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.ORCID 0000-0001-7052-1651 Guillermo Delgado-GarcíaDepartment of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.ORCID 0000-0002-3123-5879 Navprabhjot KaurDepartment of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Michaela-Pauline LuxSocial Work in Epilepsy Association, Kehl-Kork, Germany.
Heiko StempfleGerman Epilepsy Association, Berlin, Germany.
Chantal DepondtDepartment of Neurology, Erasme Hospital, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.ORCID 0000-0002-8452-5319 Reetta KälviäinenKuopio Epilepsy Center, Neurocenter, Kuopio University Hospital, Member of EpiCARE ERN, Kuopio, Finland.ORCID 0000-0003-2935-5131 Felix RosenowGoethe University Frankfurt, University Hospital, Epilepsy Center Frankfurt Rhine-Main, Department of Neurology, Frankfurt, Germany.ORCID 0000-0002-3989-7471 Sophie von BrauchitschGoethe University Frankfurt, University Hospital, Epilepsy Center Frankfurt Rhine-Main, Department of Neurology, Frankfurt, Germany.ORCID 0000-0001-8740-9279 Karl Martin KleinDepartment of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.ORCID 0000-0002-6654-1665 Andreas G ChiocchettiGoethe University Frankfurt, University Hospital, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Frankfurt, Germany.ORCID 0000-0002-7329-9985 Funding
Center for Common Disease GeneticsUM1HG008895 · NHGRI · BROAD INSTITUTE, INC. · PI DALY, MARK JOSEPH, GABRIEL, STACEY · 2016 to 2020
$111.2MPowering whole genome sequence-based genetic discovery for common human diseases- Extended 2021-2022.U01HG009088 · NHGRI · HARVARD SCHOOL OF PUBLIC HEALTH · PI LIN, XIHONG, NEALE, BENJAMIN MICHAEL · 2016 to 2021
$5.1MEpi25 Clinical Phenotyping R03R03NS108145 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LOWENSTEIN, DANIEL H · 2018 to 2019
$137kNHGRI NIH HHS U01 HG009088NHGRI NIH HHS UM1 HG008895NINDS NIH HHS R03 NS108145
6 · The paper itselfAbstract
Epilepsy affects around 1% of the global population and often requires long-term treatment with antiseizure medications (ASMs). However, the current treatment strategy is based on clinical acumen and trial and error, resulting in only about 50% of patients remaining seizure-free for at least 12 months with first-line ASMs. Valproic acid (VPA) is a commonly prescribed first-line ASM, yet <50% of patients experience inadequate seizure control (ISC) or unacceptable adverse reactions (UARs), necessitating discontinuation. We developed a predictive algorithm to support VPA treatment decisions in eligible epilepsy patients integrating in-vitro data, genetic data and previous knowledge. Our approach is based on genetic variations in genes associated with VPA pharmacodynamics and -kinetics, as well as the response of human neurons to VPA (
Indexed as
Antiseizure medicationsBiomarker-based Machine Learning ClassifierPersonalized treatment
Identifiers
PMID40909818
PMCPMC12407597
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390